GNI Group Ltd. (JP:2160)
:2160
Want to see JP:2160 full AI Analyst Report?
2160 Stock Chart & Stats
¥3370.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥3370.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥2,112.00 - ¥4,410.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)969.16K
Market Cap
¥174.55B
Enterprise Value¥156.33B
Total Cash (Recent Filing)¥21.10B
Total Debt (Recent Filing)¥5.37B
Price to Earnings (P/E)―
Beta1.15
Next Earnings
May 15, 2026EPS Estimate
-2.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-74.44
Shares Outstanding55,767,544
10 Day Avg. Volume1,104,200
30 Day Avg. Volume969,156
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,800.00Price Target Upside12.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)53.4
Revenue Forecast (FY)¥33.25B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low debt-to-equity (~0.13) and materially higher equity provide financial resilience, lowering bankruptcy and refinancing risk. This structural balance-sheet strength supports R&D funding flexibility and partnership negotiations over the next several quarters without immediate financing pressure.
Sustained Revenue GrowthA multi-year revenue growth trend with a 2025 rebound indicates underlying product or market traction. Durable top-line expansion supports scale economics, investment in pipeline commercialization, and provides a foundation for margin recovery if costs are managed.
Diversified Biopharma Revenue ModelMultiple revenue channels—direct product sales plus licensing, collaborations and royalties—reduce dependence on any single product launch. This structural diversification improves resilience to clinical or market setbacks and supports long-term cash-flow optionality via partnerships.
Bears Say
Weak Cash GenerationTwo consecutive years of negative operating and free cash flow show the business is not self-funding and increases reliance on external financing or partner milestones. Persistent cash burn elevates execution and dilution risk and constrains discretionary investment in commercialization.
Recent Profitability CollapseA swing to meaningful net losses in 2025 materially weakens earnings power and suggests structural cost or revenue timing issues. If losses persist, management must alter strategy, cut costs, or secure funding, each of which can slow long-term growth and value capture.
Volatile Earnings QualityHigh gross margins alongside collapsing operating/net margins point to volatile operating costs or one-off charges, reducing earnings quality and forecasting reliability. This volatility complicates planning, partnership valuations, and long-term margin recovery prospects.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥2112.00 and its highest was ¥4410.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥174.55B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is May 15, 2026 which is in 21 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on Feb 13, 2026. The company reported -¥74.44 earnings per share for the quarter, missing the consensus estimate of ¥224.642 by -¥299.082.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is -2.74.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 55,767,544 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -¥74.44 in its last earnings report, missing expectations of ¥224.642. Following the earnings report the stock price went down -3.49%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
2160 Stock 12 Month Forecast
Average Price Target
¥3,800.00
▲(12.76% Upside)
Technical Analysis
Peptidream
―
SanBio Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---